Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company has submitted an application of the additional indication of Takepron capsules 15 and Takepron OD tablets 15 to the Ministry of Health, Labour and Welfare for prevention of onset of low-dose aspirin related gastric and duodenal ulcer.
Subscribe to our email newsletter
Takeda said that it conducted the Phase III trial of Takepron for the treatment of Japanese patients who take low-dose aspirin in long period and submitted an application for an additional indication of prevention of onset of low-dose aspirin related gastric and duodenal ulcer based on the result of the trial.
Once this application is approved, Takeda expects to help patients taking aspirin with Takepron for prevention of onset of low-dose aspirin ulcer to allow extended use of low-dose aspirin.
Takepron is a proton pump inhibitor discovered by Takeda and has been launched since 1992 in Japan.